

FIG. 1




FIG. 2




FIG. 3

LOESS Regression Plot of Bilirubin Through Week 48 by Dose Level in Resamirigene Bilparvovec study




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5A




FIG. 5B





FIG. 6



*Control data included for study participants who died during INCEPTUS

FIG. 7C




FIG. 7D

Dose (vg/kg)	Baseline (Least Squares Mean ± Standard Error)	Week 48 (Least Squares Mean ± Standard Error)	Change
1 × 10 ¹⁴ (n=6)	30.0 ± 6.9	73.8 ± 8.5	+43.8
3 × 10 ¹⁴ (n=17)	24.3 ± 4.1	71.5 ± 5.4	+47.2
Control (n=15)	35.4 ± 4.4	29.7 ± 5.6	-5.7

FIG. 8A




FIG. 8B

Dose (vg/kg)	Baseline (Least Squares Mean ± Standard Error)	Week 48 (Least Squares Mean ± Standard Error)	Change
1 × 10 ¹⁴ (n=6)	37.7 ± 3.6	56.5 ± 3.6	+18.8
3 × 10 ¹⁴ (n=17)	30.7 ± 2.1	54.4 ± 3.3	+19.6
Control (n=15)	33.0 ± 2.3	36.4 ± 3.1	+4.8

FIG. 9A




FIG. 9B

	Motor milestone	Dose (vg/kg)		
		1 × 10 ¹⁴	3 × 10 ¹⁴	Control
Participants/Total Participants	Sit unassisted for ≥30 s	6/6 (100%)	13/17 (77%)	5/15 (33%)
	Raise to stand	5/6 (83%)	2/17 (12%)	0/15 (0%)
	Walk unsupported	5/6 (83%)	1/17 (6%)	0/15 (0%)

FIG. 10A




FIG. 10B




FIG. 11




FIG. 12




FIG. 13




FIG. 14





FIG. 15



Scale bars indicate 100 μm.